Restock in progress. Add your email and we will tell you the moment this compound is back in stock.
One email when this is back in stock. No spam, unsubscribe anytime.
CJC-1295 + Ipamorelin is a research blend that combines two distinct synthetic peptides in a single lyophilised vial: CJC-1295, an analog of growth hormone-releasing hormone (GHRH) built on the GRF(1-29) backbone, and Ipamorelin, a five-amino-acid growth hormone secretagogue, or ghrelin-receptor agonist. The two compounds belong to different peptide classes and are supplied together for research use.
At the molecular level, CJC-1295 has been characterised in the preclinical literature as a long-acting agonist at the GHRH receptor on the anterior pituitary, while Ipamorelin has been characterised as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a), the ghrelin receptor. The blend is supplied as a research compound and is not intended for human or veterinary use.
Each component of this blend has been characterised in preclinical laboratory models. The primary studies below are grouped by component: the CJC-1295 set, in cultured rat pituitary cells and animal models, examined receptor agonism, serum-albumin conjugation, plasma persistence, and endpoints across the growth hormone and IGF-1 axis; the Ipamorelin set, in primary rat pituitary cell cultures and adult rat models, assayed receptor binding at the growth hormone secretagogue (ghrelin) receptor, pituitary growth hormone secretion, and measured physiological parameters. The literature is preclinical; it describes the compounds, not any outcome in humans.
Animal and in vitro
GRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats, identifying CJC-1295 as a long-acting GRF analog
In cultured rat anterior pituitary cells and in rats, the study assayed GRF-receptor agonist binding and growth hormone secretion, confirmed covalent conjugation of the bioconjugate to circulating serum albumin, and measured plasma persistence beyond 72 hours as a pharmacokinetic endpoint.
Read the study ↗
Animal model
A long-acting GHRH analog dosed once daily in the GHRH-knockout mouse model
In a GHRH-knockout mouse model dosed at 24, 48, and 72 hour intervals over five weeks, the study measured pituitary and circulating endpoints across the growth hormone and IGF-1 axis as a function of the long-acting GHRH analog and its dosing interval.
Read the study ↗
Animal and in vitro
Ipamorelin characterised as a selective growth hormone secretagogue receptor agonist
In primary rat pituitary cell cultures and in anaesthetised rats and conscious swine, receptor-binding and dose-response assays measured growth hormone secretion at the growth hormone secretagogue receptor, with the response gauged against parallel ACTH and cortisol measurements across the dose range tested as a selectivity endpoint.
Read the study ↗
Animal model
Ipamorelin and GH-releasing peptide-6 assayed against bone mineral content in an adult female rat model
In adult female rats dosed by daily subcutaneous administration against vehicle controls over a multi-week period, the study measured body weight change and total and cortical bone mineral content by densitometry and chemical analysis as physiological endpoints, comparing ipamorelin with GH-releasing peptide-6.
Read the study ↗
Full documentation, on the record. A Certificate of Analysis and a Safety Data Sheet are available on request for every batch.
View the Certificate of Analysis ↗Links open the original study on PubMed. For research and educational purposes, descriptive of the published preclinical literature, not therapeutic claims about any ai-peptides product.
